medcareernews.com
Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care - MedCareer News
THOUSAND OAKS, Calif., June 18, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating Vectibix® (panitumumab) and best supportive care (BSC) met...